| 类风湿关节炎药物治疗基因多态性研究进展 |
| |
| 引用本文： | 赵智明,蔡辉. 类风湿关节炎药物治疗基因多态性研究进展[J]. 国际免疫学杂志, 2017, 40(4). DOI: 10.3760/cma.j.issn.1673-4394.2017.04.025 |
| |
| 作者姓名： | 赵智明 蔡辉 |
| |
| 作者单位： | 210002,南京军区南京总医院中西医结合科 |
| |
| 基金项目： | 南京军区南京总医院科研项目资助(2013056)Nanjiang General Hospital of Nanjing Military Research Fund |
| |
| 摘 要： | 类风湿关节炎(RA)是一种系统性疾病,可致关节破坏和残疾.治疗以传统DMARDs和生物制剂为主.药物疗效与患者基因多态性密切相关.药物主要包括甲氨蝶呤、来氟米特、柳氮磺胺吡啶和生物制剂如TNF拮抗剂、妥珠单抗、力妥昔单抗等.RA患者遗传背景是影响药物疗效的重要因素,必然对个体化治疗产生深远影响,因而研究基因多态性与RA患者疗效反应的相关机制具有重要意义.
|
| 关 键 词： | 多态性 类风湿关节炎 治疗 生物制剂 甲氨蝶呤 |
The effect of gene polymorphisms on therapy of rheumatoid arthritis |
| |
| Zhao Zhiming,Cai Hui. The effect of gene polymorphisms on therapy of rheumatoid arthritis[J]. International Journal of Immunology, 2017, 40(4). DOI: 10.3760/cma.j.issn.1673-4394.2017.04.025 |
| |
| Authors: | Zhao Zhiming Cai Hui |
| |
| Abstract: | Rheumatoid arthritis (RA) is a systemic disease leading to joint destruction.The therapy of RA is mainly based on disease modifying anti-rheumatic drugs (DMARDs) and biological drugs.The response to treatment is different among patients.Therefore,we have searched for factors that may predict the efficacy and toxicity during therapy in individual patients.This review presents the role of genetic polymorphisms as predictors of the efficacy and toxicity during the therapy of rheumatoid arthritis patients with disease modifying antirheumatic drugs (methotrexate,leflunomide,sulfasalazine) and biological drugs (anti-TNF-alpha antagonists,Tocilizumab,Rituximab).We are still far from applying pharmacogenetic tests in routine clinical practice that can predict the outcome of treatment,but genetic background will be the most important factor in personalizing therapy. |
| |
| Keywords: | Polymorphis Rheumatoid arthritis,Therapy Biological drugs Methotrexate |
| 本文献已被 万方数据 等数据库收录！ |
|
